

# 9

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.


Dated: March 11, 2003

Signature:

Thomas J. Wrona, Ph.D.

Docket No.: 27373/36638A  
(PATENT)

K.T.  
5/20  
C



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Weichselbaum, et al.

Application No.: 09/964,042

Group Art Unit: 1635

Filed: September 26, 2001

Examiner: J. E. Angell

For: Treatment of Tumors with Genetically  
Engineered Herpes Virus

**AMENDMENT AND RESPONSE TO THE OFFICE ACTION  
OF OCTOBER 11, 2002**

Commissioner for Patents  
Washington, DC 20231

**RECEIVED**

APR 22 2003

Dear Sir:

OFFICE OF PETITIONS

In an Office Action dated October 11, 2002, pending claims 1 through 9 were rejected under 35 USC §112, first and second paragraphs. In view of the amendments and remarks made herein, reconsideration is respectfully requested.

**I. AMENDMENT**

**In the Specification**

Please replace the text inserted before the first line by preliminary amendment on September 26, 2001 with the following:

-This is a Continuation of U.S. application Serial No. 09/629,021, filed July 31, 2000, now abandoned, which is a Continuation of U.S. application Serial No. 09/244,748, filed February 5, 1999, now abandoned.

**In the Claims**

Please amend claim 1 as indicated below.

1. [Twice Amended] A method for reducing tumor mass comprising the step of administering to an individual suffering from cancer an amount of a Herpes simplex